BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Regeneron (REGN), Vertex Pharmaceuticals (VRTX) and BioNTech (BNTX) are three large biotech stocks that are worth betting on in the current scenario.

Will 2022 Be a Better Year for Biotech Than 2021? 3 Big Picks

Adagio Therapeutics

Novavax

Pacific Biosciences of California

Could these biotech stocks be poised for gains in 2022?

5 Top Biotech Stocks To Watch In January 2022

Pfizer

A fresh Supreme Court ruling does neither stock any favors.

Why Pfizer and BioNTech Got Thrashed on Thursday

Moderna

Shares of vaccine makers, including Moderna Inc (NASDAQ:MRNA), BioNTech SE – ADR (NASDAQ:BNTX) and Novavax, Inc. (NASDAQ:NVAX), are all trading lower as the sector continues to pull back following 2021 strength, with investors continuing to weigh sector outlook going into 2022. The US Supreme Court today blocked President Biden's workplace vaccine-or-test mandate for larger employers.

What's Going On With Moderna, BioNTech And Novavax Stock Today

The successful rollout of a revolutionary vaccine leaves the immunotherapy specialist primed for further gains.

Why Shares of BioNTech Rose 216% in 2021

BioNTech SE (BNTX) CEO Ugur Sahin on JPMorgan 40th Annual Healthcare Conference (Transcript)

BioNTech SE (NASDAQ: BNTX) said it's working with London-based AI developer InstaDeep to develop a new computational method that analyzes sequencing data and predicts high-risk variants SARS-CoV-2. The early warning system combines structural modeling of the SARS-CoV-2 spike protein, and AI algorithms to flag potentially high-risk variants entered into SARS-CoV-2 sequence data repositories “within less than a day,” based on metrics scoring their fitness and their immune escape properties.

BioNTech Partners With London-Based AI Developer To Predict COVID-19 Variants

Germany's BioNTech said on Tuesday it would likely generate up to 17 billion euros ($19 billion) in 2022 revenue from the COVID-19 vaccine it co-developed with partner Pfizer.

BioNTech eyes up to 17 billion euros in vaccine revenue in 2022

Shares of BioNTech SE BNTX, +8.57% were down 0.6% in premarket trading on Tuesday after the company said it developed a new system with InstaDeep Ltd. that uses a mix of modeling and artificial intelligence to predict high-risk new SARS-CoV-2 variants, based on publicly available virus sequences.

BioNTech, InstaDeep create new system to identify high risk SARS-CoV-2 variants

MAINZ, Germany and LONDON, United Kingdom, January 11, 2022 — BioNTech SE (Nasdaq: BNTX, “BioNTech”) and InstaDeep Ltd (“InstaDeep”) today announced the development of a new computational method that analyses worldwide available sequencing data and predicts high-risk variants of SARS-CoV-2. The Early Warning System (EWS) developed in collaboration by BioNTech and InstaDeep is based on artificial intelligence (AI) calculated immune escape and fitness metrics.

BioNTech and InstaDeep Developed and Successfully Tested Early Warning System to Detect Potential High-Risk SARS-CoV-2 Variants

MAINZ, Germany and CAMBRIDGE, UK, January 10, 2022 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Crescendo Biologics Ltd (“Crescendo”), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announced that they have entered a multi-target discovery collaboration to develop novel immunotherapies for the treatment of patients with cancer and other diseases. The initial term of the discovery collaboration is three years.

BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision Immunotherapies

Pfizer (PFE) and BioNTech (BNTX) plan to develop an mRNA-based vaccine for shingles after witnessing success with their COVID-19 vaccine.

Pfizer and BioNTech to Make mRNA-Based Shingles Vaccine

If successful, the vaccine could be the first mRNA shot for shingles.

Pfizer, BioNTech Will Develop mRNA Shingles Vaccine After Covid-19 Shot Success

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have announced a new research, development, and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles. The agreement marks the third collaboration between Pfizer and BioNTech in the infectious diseases field, following influenza and COVID-19 vaccine collaborations initiated in 2018 and 2020.

After Successful COVID-19 Vaccine, Pfizer, BioNTech Come Together For mRNA-Based Shingles Vaccine

Shares of Pfizer Inc. PFE, -3.74% rose 1.6% in premarket trading Wednesday and BioNTech SE BNTX, -3.35% gained 0.9%, after the drug makers said they will collaborate in developing a potential first mRNA-based shingles vaccine. The companies said they will leverage the antigen technology identified by Pfizer and BioNTech's mRNA platform technology, which were used to develop their COVID-19 vaccine.

Pfizer, BioNTech to collaborate in developing mRNA-based shingles vaccine

NEW YORK and MAINZ, Germany, January 5, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a new research, development and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles (herpes zoster virus, or HZV), a debilitating, disfiguring and painful disease that impacts about one in three people in the United States during their lifetime. The collaboration builds on the companies' success in developing the first approved and most widely used mRNA vaccine to help prevent COVID-19. This is the third collaboration between Pfizer and BioNTech in the infectious diseases field, following the influenza vaccine collaboration initiated in 2018 and the COVID-19 vaccine collaboration initiated in 2020.

Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine

This stock is a bet on the idea that BioNTech can become a Next-Gen drug development platform able to develop new solutions to attack infectious diseases, cancer, and other conditions. BioNTech, unlike Moderna, is not exclusively an mRNA platform company. BioNTech is building out multiple platforms that include an Antibody platform, a Cell Therapies platform, and a Small Molecule Immunomodulators platform.

BioNTech: Profit Off Of Next-Gen Vaccines And Therapies

The current investor trend isn't the biotech stock's friend.

Why BioNTech Stock Tumbled on Tuesday

FDA authorizes the booster shot of Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine for adolescents 12 through 15 years of age.

Pfizer, BioNTech Booster Gets FDA Nod for 12 to 15-Year Olds

Investors appear to be seeing a future where COVID-19 vaccines aren't needed nearly as much.

Why Pfizer, BioNTech, and Moderna Stocks Are Falling Today

The agency also greenlights a booster for younger children who are immunocompromised.

FDA authorizes COVID boosters for kids ages 12 to 15

The new approval comes as the Omicron variant surges through the US, driving up new COVID-19 cases to record highs.

FDA approves Pfizer's COVID-19 vaccine booster shot for children ages 12 and up

Pfizer Inc. PFE, -3.95% and BioNTech SE BNTX, -4.93% announced Monday that the U.S. Food and Drug Administration has granted Emergency Use Authorization of a booster dose of the companies' COVID-19 vaccine into people ages 12 years and older. Previously, the FDA had only authorized a booster for people aged 16 years and older.

Pfizer, BioNTech booster shot EUA expanded to include children 12 years old

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) of a booster dose of the Pfizer-BioNTech COVID-19 Vaccine to include individuals 12 years of age and older. The booster dose is the same dosage strength (30-µg) as the dose approved in the primary series. A booster dose of the Pfizer-BioNTech COVID-19 Vaccine was previously authorize

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older

New Covid infections have hit a pandemic high in the U.S. as the highly contagious omicron variant has supplanted delta as the dominant strain.

News for BioNTech SE Stock (BNTX)